Addiction

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory Momentum Seven...

BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum

VANCOUVER, BC / ACCESS Newswire / April 28, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience...

Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty

-- Findings show significant reductions in opioid consumption, healthcare resource utilization, and total medical costs --BRISBANE, Calif., April 27, 2026...

Red Light Holland Highlights U.S. FDA-Authorized Study Supporting Multi-Session Psilocybin Therapy using Filament Health’s Patented PEX010 Botanical Drug Candidate

Study conducted under U.S. FDA Investigational New Drug (IND) authorization by Dr. Anthony Back at the University of WashingtonSecond psilocybin...

Sparian Biosciences Announces Initiation of Phase 1 Clinical Trial of SBS-147 Next Generation Arylepoxamide Agonist for the Treatment of Pain Funded by a $15M NIH Grant

Phase 1 clinical trial will evaluate the safety, tolerability, and pharmacokineticsSBS-147 is a novel and potent oral analgesic with a...

Truth Initiative’s EX Program Launches First Campaign to Include Nicotine Pouches as Gen Z Faces Troubling Rise in Use of Multiple Products

New Outsmart Nicotine ads, which also include cigarettes and e-cigarettes, highlight the cycle of stress, cravings and nicotine addiction, and...

error: Content is protected !!